Possible link of food-derived advanced glycation end products (AGEs) to the development of diabetes

Medical Hypotheses

Volumn 71, Issue 6, 2008, Pages 876-878

  Yamagishi, S ^a   Matsui, T ^a   Nakamura, K ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL DAMAGE; DIABETES MELLITUS; DIETARY INTAKE; FOOD INTAKE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN GLYCOSYLATION; RISK FACTOR;

DIABETES MELLITUS; DIET; FOOD ANALYSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; OBESITY;

ANIMALIA;

EID: 53949108742     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.07.034     Document Type: Article

References (12)

1. Li G., Wang J., Gregg E.W., et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: a 20-year follow-up study. Lancet 371 (2008) 1783-1789
2. Yamagishi S., and Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Design 11 (2005) 2279-2299
3. Yamagishi S., Nakamura K., Matsui T., et al. Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease. Cardiovasc Ther 26 (2008) 50-58
4. Yamagishi S., Matsui T., and Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 8 (2007) 1138-1143
5. Matsuoka T., Kajimoto Y., Watada H., et al. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest 99 (1997) 144-150
6. Unoki H., and Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Design 14 (2008) 987-989
7. Yamagishi S., Ueda S., and Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Design 13 (2007) 2832-2836
8. Vlassara H. Advanced glycation in health and disease: role of the modern environment. Ann NY Acad Sci 1043 (2005) 452-460
9. Hofmann S.M., Dong H.J., Li Z., et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 51 (2002) 2082-2089
10. Sandu O., Song K., Cai W., et al. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 54 (2005) 2314-2319
11. Peppa M., He C., Hattori M., et al. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 52 (2003) 1441-1448
12. Ihnat M.A., Thorpe J.E., and Ceriello A. Hypothesis: the 'metabolic memory', the new challenge of diabetes. Diabetic Med 24 (2007) 582-586